Adjusted gross profit up 90%, driven by acquisitions and organic growth
Adjusted EPS up 25% to 35.0p (2015: 28.0p)
Net debt decreased £8.1m to £68.1m, after £28.5m spent on acquisitions
Full year dividend increased 18% to 4.0p (2015: 3.4p)
Strongest performances by Specialty Pharmaceuticals, driven by revitalisation of newer products, and CTS
Integration of Idis and Link acquisitions substantially complete
Acquisition of Totect and Foscavir bag line extension enhances Specialty Pharmaceuticals portfolio
Shaun Chilton to become CEO on 11 November 2016, when Peter George steps down
(see separate announcement)
Peter George, Chief Executive Officer, said:
"The acquisition and integration of Idis and Link Healthcare have transformed the Group over the last 18 months.
"We have achieved our ambition to become the global market leader in the management and supply of both unlicensed and clinical trial medicines, and expanded our global footprint.
"Alongside the significant strategic progress, we have also delivered a strong financial performance with good levels of organic growth combining with the acquisitions to increase adjusted EPS* by 25%.
"The newer products in our Specialty Pharmaceuticals portfolio are making good progress, demonstrating the effectiveness of our revitalisation model and we saw another excellent year in the Clinical Trial Services division."